Answer
Yes, interstitial lung disease (ILD)-like events, including fatalities, have been reported uncommonly in patients receiving Tarceva (erlotinib) for NSCLC, pancreatic cancer or other advanced solid tumours.
Sources for this answer
- Tarceva 25 mg, 100 mg & 150 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 11Document updated
Sources checked